- Home
- SOBO vs ALKS Comparison
SOBO vs ALKS Comparison
Compare SOBO & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOBO
- ALKS
- Stock Information
- Founded
- SOBO 2024
- ALKS 1987
- Country
- SOBO Canada
- ALKS Ireland
- Employees
- SOBO N/A
- ALKS N/A
- Industry
- SOBO
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- SOBO
- ALKS Health Care
- Exchange
- SOBO NYSE
- ALKS Nasdaq
- Market Cap
- SOBO 5.7B
- ALKS 5.6B
- IPO Year
- SOBO N/A
- ALKS 1991
- Fundamental
- Price
- SOBO $24.03
- ALKS $34.35
- Analyst Decision
- SOBO Hold
- ALKS Buy
- Analyst Count
- SOBO 2
- ALKS 12
- Target Price
- SOBO $27.00
- ALKS $38.36
- AVG Volume (30 Days)
- SOBO 674.9K
- ALKS 2.0M
- Earning Date
- SOBO 03-05-2025
- ALKS 04-30-2025
- Dividend Yield
- SOBO 4.16%
- ALKS N/A
- EPS Growth
- SOBO N/A
- ALKS 3.47
- EPS
- SOBO 1.52
- ALKS 2.17
- Revenue
- SOBO $2,120,000,000.00
- ALKS $1,557,632,000.00
- Revenue This Year
- SOBO N/A
- ALKS N/A
- Revenue Next Year
- SOBO N/A
- ALKS $4.37
- P/E Ratio
- SOBO $15.77
- ALKS $15.61
- Revenue Growth
- SOBO 5.74
- ALKS N/A
- 52 Week Low
- SOBO $21.12
- ALKS $22.90
- 52 Week High
- SOBO $27.60
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- SOBO N/A
- ALKS 55.15
- Support Level
- SOBO N/A
- ALKS $33.61
- Resistance Level
- SOBO N/A
- ALKS $35.68
- Average True Range (ATR)
- SOBO 0.00
- ALKS 0.94
- MACD
- SOBO 0.00
- ALKS -0.20
- Stochastic Oscillator
- SOBO 0.00
- ALKS 26.06
About SOBO SOUTH BOW CORPORATION
South Bow Corp is a energy infrastructure company. The company is engaged in constructing pipelines system safely transports liquids like crude oil, across Canadian provinces, U.S. states, and Gulf coasts.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.